Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I recall an issue come through at one point that the company had to voluntary remove it due to some issues...either packaging errors or wrong mg issues. Don't remember when that was though.
Also do not discount the potential of Isradapine in pts with Parkinson's. Their is a major multi-site study underway through the Michael J. Fox foundation through Northwestern as the PI site. Would exponentially change that market value.
Hope folks understand that any Epic sale is infusion of dollars into Elite. This is quite misleading.
Where are you coming up with these numbers? I think most folks are targeting between 1.5-2, no?
I missed, that. Thought it was just the spelling.
They had to change"eudragit" to "EUDRAGIT" in each claim!
Thanks for the update Lasers. This is actually looking good.
Are you kidding me? a. he was wrong. b. he has been hurting this boards validity more than anyone else. I have been invested in Elite for 10 years and the last few years all you have seen from him is over-the-top grandeur.
Thanks. I know. We are well aware of the other boards you post on. Thanks for being a mod and you bring to this board.
No you don't. It is so tiring and has been for years... I give more credence to LOLs posts than yours.
Not the case. I see people daily who never had a single red flag for abusing anything in their history and got hooked on Oxy after post-op back or spine surgery, horrible trauma etc., and eventually moved onto heroin. We are talking about all sorts of folks, white collar, blue collar, gov't leaders, every color and size. It is powerful stuff.
Frankly Elite's nor anyone else's technology will do anything for folks who are already in the thick of this epidemic or those who transitioned from Oxy to Heroin. But, please back of and understand the impetus and driving force behind this epidemic. A lot of these folks are not your typical heroin user. They are people who started taking painkillers through appropriate channels or folks who tried Oxy and were easily hooked. Heroin is a natural next step. Particularly when you look at the street cost of opioids where 1 mg of Oxy is $1. That means for a standard 80 mg pill, that costs $80 on the street. Most folks abusing Oxy are taking many more than (1) 80mg pill per day and the switch to Heroin is a matter of economics. Heroin is very cheap ($4-$20 per bag). What Elite and other's ART can do is save future generations of falling victim to this deadly epidemic affecting every single "type" of population in the country. It will also allow clinicians to affectively and appropriately treat pain - which is an incredibly complicated part of the healthcare delivery system - better and most importantly with less negative downstream affects. 75% of U.S. drug overdoses are opioid related. In, NYC, heroin overdoses are up >80% in the last two years. In Massachusetts, where I live, accidental poisoning (OD) has taken the number one spot for the first time in our state's history for accidental deaths. There is a spiderweb affect due to the epidemic. Opioid abuse and addiction costs about 485 BILLION annually (just in the U.S.); is linked to about 50% of major crime. Elite is about to enter this ART market and they won't be the only one... But any of these companies bringing true ART to market will significantly impact and slowly change the tide of the current epidemic and those companies also stand to make incredible amounts of money on these drugs and rightfully so because if you think about the negative downstream affects currently associated with the Oxy/Heroin epidemic, ART, is a win-win for everyone.
I personally anticipate a partner announcement as soon as the trials are completed. IMO it has hinged on patenting (which they now have) and data (which they almost have). If the data is not there then no deal. There should be no reason for the data to not be solid as this has already been previously studied and the results were very positive and presented at the American Academy of Pain Medicine IN 2008. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92957867
The only real downside I see is the company not developing into a pharma company with ART products (which I don't see not happening) and ends up being a decent profitable generic company. Anyway you look at it, Elite is and has been greatly undervalued.
The following table sets forth the amount of gross proceeds we would receive from Lincoln Park from our sale of shares to Lincoln Park under the Purchase Agreement at varying purchase prices:
$ 0.07 76,537,785 $5,250,000
$ 0.15 69,595,782 $10,000,000
$ 0.25 42,929,115 $10,000,000
$ 0.35 31,500,544 $10,000,000
I encourage folks to read the actual filing about the LPC financing. This is what will allow Elite to move forward with trials on their own (adding significantly more value to the company).
http://www.sec.gov/Archives/edgar/data/1053369/000114420413024005/v342010_s1.htm
Purchase of Shares Under the Purchase Agreement
Under the Purchase Agreement, on any business day selected by us, we may direct Lincoln Park to purchase up to $80,000 worth of our common stock on any such business day so long as two business days have passed since the last purchase. On any day that the closing sale price of our common stock is not below $.12 the purchase amount may be increased, at our sole discretion, to up to $150,000 per purchase, on any day that the closing sale price of our common stock is not below $.175 the purchase amount may be increased, at our sole discretion, to up to $250,000 per purchase, on any day that the closing sale price of our common stock is not below $.25 the purchase amount may be increased, at our sole discretion, to up to $350,000 per purchase and on any day that the closing sale price of our common stock is not below $.40 the purchase amount may be increased, at our sole discretion, to up to $500,000 per purchase.
Under the terms of the agreement, there are no upper limits to the price that LPC may pay to purchase Elite’s common stock. Elite will control the timing and the amount of shares to be sold. LPC has no right to require any sales and is obligated to purchase common stock as directed by Elite. Under the terms of the agreement, LPC has agreed not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Elite’s shares of common stock. In consideration for entering into the agreement, Elite has issued shares of common stock to LPC as a commitment fee and will issue additional commitment fee shares in proportion to the amount of shares purchased by LPC under the agreement.
That clears that up. Thanks.
Why do you see ALO-02 not having the same stability issues? This is a single bead technology.
Nope Thursday
Remember when Jerry Treppel said this:
"And most importantly, and this is really going to differentiate this year from last year, is to focus on the development of the abuse resistant products, which is really the reason this Company, to an extent, was founded, is to do those products. And we are closer now than we ever have been. We think within this fiscal year those will be scaled up and ready to enter biostudies.
If you're familiar with the valuation accretion curve in pharmaceuticals, a little effort goes a long way in terms of creating value in pharmaceutical products. What I mean by that is that if you have a formula that's worth X, if you can make a pilot batch, it's X times two. If you can make a commercial batch, well, it's X times some number, and finally, if you can do a bio study that's successful, well, it's X times many, many times. And that's our goal here. Okay?
So for not an extraordinary amount invested, you get a lot in return."
You would think there are far more creative ways to signal? But seriously, pinch my butt, this is exciting!
I think I've paid 10K in broker fees so far...This is sub $1 stock right now but it is not a penny stock. Some unfortunate company/management events have turned this into an opportunity for many folks. Welcome aboard.
People must be finding out about the "Also Ran" patents!
Naloxone can be defeated. That drug is not true ART.
Elite will be making Embeda for Actavis. This post can serve as your link.
Elite is about to make a better Embeda, Targiniq (Naloxone) is not a true ART drug. I have colleagues in Europe who have been watching that drug be abused for years. Also, please provide a link regarding ALO-02.
Here are some facts...
Nasrat Hakim, current president of Elite was CEO of Mikah Pharma and Vice President, Quality, Compliance and Technical Services at Actavis. He is also Consultant to the CEO of Epic Pharma.
Why would Actavis let a VP (Hakim) start another company (Mikah Pharma) and serve as consultant to Epic's CEO unless they had their hands in it?
Ashok Nigalye, Ph.D., Chief Scientific Officer at Elite used to serve as Vice President of Scientific Affairs and Operations of Actavis Totowa LLC. He came over the same time as Jerry Treppel.
Carter J. Ward, CPA, CSCP, Chief Financial Officer at Elite was previously at Actavis Group and its U.S. subsidiary, Amide Pharmaceuticals (where Actavis got their OXY).
The original EPIC strategic alliance drugs was a mirage. Epic bailed Elite out from what the previous management did (delisted from NYSE and on the edge of bankruptcy) for a reason. Do you think Epic is not connected to Actavis? Did you know that Epic will be manufacturing Oxy for Actavis?
If folks have been paying attention the last three years it has become quite clear that all roads lead to Actavis. It is not about if anymore, it is about when. Elite will announce a partnership with Actavis for at least one ART product.
Here is a great link that shows the tie between Elite and Actavis:
Actavis: Abuse-Deterrent Opioid Connections
http://seekingalpha.com/article/1463281-actavis-abuse-deterrent-opioid-connections?source=email_rt_article_title
My thoughts are on Monday Epic sold 805,000 shares at .18 for < $150K. Epic maintains roughly 70 million shares of ELTP.
LPC is limited to 250k dollars worth of purchase per day. So that does not come even close to being part of this volume.
Thanks I fixed it!
Not sure about that. I thought that was possible at first but must submit Form 4's within 2 business days.
Actavis and others are currently looking to purchase Pfizer's generic business: http://www.reuters.com/article/2014/01/14/us-pfizer-valeant-idUSBREA0D0CZ20140114
How times have changed...
Go run a marathon somewhere else...
That reminds me... I also want to thank Dr. L for all of his DD the past couple years. If it was not for him reinforcing what we held in his expert ways I probably would have bailed.
Welcome.
Start here: http://seekingalpha.com/article/1905051-elite-pharmaceuticals-swinging-for-the-fences
My personal opinion is that this company has the technology to become one of the major players in the pain market. I bought first when it was listed in dollars under ELI ten years ago. R&D costs and mismanagement nearly bankrupted the company. They now have the patents for their technology and are doing BE trials to bring an abuse resistant product to market.
I would start with Akorn. I think that is the trajectory folks should be looking at when thinking about what Elite is about to do. http://www.nasdaq.com/symbol/akrx
Speaking of, I have not checked the European Union patents in years. Does anyone recall the application number? http://www.epo.org/searching.html
Speaking of, I have not checked the European Union patents in years. Does anyone recall the application number? http://www.epo.org/searching.html